Steven Feldman to Biological Therapy
This is a "connection" page, showing publications Steven Feldman has written about Biological Therapy.
Connection Strength
2.269
-
Ghamrawi R, Bell KA, Balogh EA, Strowd LC, Feldman SR. Current and emerging biologics for the treatment of pediatric atopic dermatitis. Expert Opin Biol Ther. 2020 12; 20(12):1435-1445.
Score: 0.738
-
Cline A, Hill D, Lewallen R, Feldman SR. Current status and future prospects for biologic treatments of psoriasis. Expert Rev Clin Immunol. 2016 Dec; 12(12):1273-1287.
Score: 0.545
-
Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013 Aug; 14(4):315-26.
Score: 0.445
-
Lewis DJ, Chan WH, Hinojosa T, Hsu S, Feldman SR. Mechanisms of microbial pathogenesis and the role of the skin microbiome in psoriasis: A review. Clin Dermatol. 2019 Mar - Apr; 37(2):160-166.
Score: 0.162
-
Hoffman MB, Hill D, Feldman SR. Current challenges and emerging drug delivery strategies for the treatment of psoriasis. Expert Opin Drug Deliv. 2016 Oct; 13(10):1461-73.
Score: 0.135
-
Huang W, Cordoro KM, Taylor SL, Feldman SR. To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis. J Am Acad Dermatol. 2008 Jun; 58(6):970-7.
Score: 0.077
-
Feldman SR, Gelfand JM, Stein Gold L, Jones SD. The role of topical therapy for patients with extensive psoriasis. Cutis. 2007 Jan; 79(1 Suppl 2):18-31.
Score: 0.071
-
Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Inpatient management of severe psoriasis. J Drugs Dermatol. 2005 Sep-Oct; 4(5):564-70.
Score: 0.064
-
Ahn CS, Dothard EH, Garner ML, Feldman SR, Huang WW. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2015 Sep; 73(3):420-8.e1.
Score: 0.032